quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:11·105d
INSIDERFiling
Lyra Therapeutics Inc. logo

President & CEO Palasis Maria sold $5,726 worth of shares (1,702 units at $3.36), decreasing direct ownership by 0.15% to 1,096,733 units (SEC Form 4)

LYRA· Lyra Therapeutics Inc.
Health Care
Original source

Companies

  • LYRA
    Lyra Therapeutics Inc.
    Health Care

Recent analyst ratings

  • May 7UpdateH.C. Wainwright$2.00
  • May 7UpdateJefferies$0.50
  • May 7UpdateBofA Securities-
  • May 6UpdateWilliam Blair-
  • Oct 6UpdateBTIG Research$15.00
  • Aug 31UpdateH.C. Wainwright$12.00

Related

  • SEC3d
    SEC Form 25 filed by Lyra Therapeutics Inc.
  • SEC6d
    SEC Form 8-K filed by Lyra Therapeutics Inc.
  • PR6d
    Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
  • SEC13d
    SEC Form 8-K filed by Lyra Therapeutics Inc.
  • INSIDER20d
    SEC Form 4 filed by Palasis Maria
  • INSIDER20d
    SEC Form 4 filed by Cavalier Jason
  • SEC23d
    SEC Form 10-K filed by Lyra Therapeutics Inc.
  • SEC28d
    SEC Form EFFECT filed by Lyra Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022